Founded in October 2003, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of Chongqing Zhifei Biological Products Co., Ltd. (stock code: 300122). It is a national high-tech enterprise that integrates the development, manufacture and sales of new vaccines, with registered capital of 830 million RMB. Zhifei Lvzhu is located in Yizhuang Estate of Zhongguancun Science Park, covering a total area of 84 mu, and owns an advanced new vaccine R&D center and a modernized GMP-certificated vaccine manufacturing site. After 15 years of innovation and development, Zhifei Lvzhu has successively been conferred Beijing “G20 Project” Innovation Leading Enterprise, Beijing Enterprise with Honesty and Credit, Beijing Patent Pilot Unit, Zhongguancun High-tech Enterprise, Zhongguancun “Ten-Hundred-Thousand-Project” Enterprise, Zhongguancun “Gazelle Enterprise” and Advanced Unit of Science and Technology Innovation in Beijing Economic and Technological Development Zone.
In June 2005, the company obtained drug manufacturing license issued by the former Beijing Food and Drug Administration. Since the company’s first product was launched in March 2008, there are 5 listed products on sale, all of which are bacterial vaccines, including Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (HIBACON®), Meningococcal Group A and C Conjugate Vaccine (MENINGACON®), Group ACYW135 Meningococcal Polysaccharide Vaccine (MENWAYC®), Haemophilus Influenzae Type b Conjugate Vaccine (Xifeibei®) and Group A and C Meningococcal Polysaccharide Vaccine (MENINCOVER ®). The sales area of the above products covers the whole China, and some products have been sold overseas. Meningococcal Groups A&C and Haemophilus b Conjugate Vaccine (HIBACON®) is the first international triple vaccine, which won the second prize of Science and Technology Award of Beijing Municipality in 2017.